# PubMed API Lead List: Biotech, Pharma & Drug Discovery
**API:** https://pubmed.built-simple.ai  
**Last Updated:** 2026-01-31  
**Target Segment:** Biotech startups, pharma companies, drug discovery platforms

---

## Why These Companies Need PubMed API

Companies in AI drug discovery, biotech R&D, and precision medicine need:
- Real-time access to medical literature for target validation
- Automated literature mining for competitive intelligence
- Integration with ML pipelines for training data
- Clinical evidence aggregation for regulatory submissions

---

## üî•üî•üî• NEW: Hot Leads Added 2026-02-07

### Lila Sciences üî•üî•üî•
**Focus:** Scientific superintelligence, autonomous AI labs for life sciences
**Funding:** $550M total ($1.3B valuation, Oct 2025)
**HQ:** Cambridge, MA
**Investors:** Flagship Pioneering, General Catalyst, Nvidia, ADIA

| Role | Name | LinkedIn |
|------|------|----------|
| CEO | Geoff von Maltzahn | General Partner at Flagship |
| CTO | Andrew Beam | Ex-Harvard |
| Chief Scientist | George Church | Harvard/MIT geneticist |
| (ex-OpenAI) | Kenneth Stanley | - |

**Why PubMed API:** Building "AI Science Factories" that automate experiment design and analysis. Their autonomous labs need real-time literature integration for hypothesis generation and validation. They partner with other biotechs - could be a platform play.

**Recent Hook:** Raised $550M in 2025 alone across 3 rounds. Nvidia invested in Oct 2025 extension.

**Outreach Angle:** "Lila's AI Science Factories could integrate PubMed for automated literature review in experiment design. We power similar autonomous research workflows."

**Email Pattern:** {f}{last}@lila.ai (e.g., gvonmaltzahn@lila.ai) ‚ö†Ô∏è CEO email not verified - use info@lila.ai
**Website:** https://lila.ai

---

### Xaira Therapeutics üî•üî•üî•
**Focus:** AI drug discovery using protein design (RFdiffusion, RFantibody)
**Funding:** $1B (largest ARCH Venture Partners initial commitment ever)
**HQ:** South San Francisco, CA
**Investors:** ARCH Venture Partners, Foresite Labs, F-Prime, NEA, Sequoia, Lux, Lightspeed

| Role | Name | Email (Verified) | LinkedIn |
|------|------|------------------|----------|
| CEO | Marc Tessier-Lavigne, PhD | ‚ö†Ô∏è Not verified | Ex-Genentech CSO, Ex-President Stanford & Rockefeller |
| CTO & Co-founder | Hetu Kamisetty | hetu.kamisetty@xaira.com | Ex-Meta, Institute for Protein Design |
| CSO | Debbie Law | debbie.law@xaira.com ‚úÖ | - |
| Co-founder | David Baker, PhD | - | Nobel potential, UW Institute for Protein Design |
| CPO | Julia Tran | julia.tran@xaira.com | - |

**Board:** Scott Gottlieb (ex-FDA Commissioner), Carolyn Bertozzi (Nobel laureate), Alex Gorsky (ex-J&J CEO)

**Why PubMed API:** Using AI for protein and antibody design - needs literature context for target validation, competitive intelligence, and connecting engineered molecules to disease biology.

**Recent Hook:** $1B funding in April 2024, now expanding team and relocating to South SF. Board is stacked with pharma heavyweights.

**Outreach Angle:** "Xaira's protein design platform could benefit from integrated literature search for target validation. PubMed API enables real-time evidence correlation with your RFdiffusion outputs."

**Email Pattern:** {first}.{last}@xaira.com ‚úÖ (Hunter.io verified)
**Website:** https://xaira.com (note: xaira.bio redirects)

---

## üî• Tier 1: High-Value Targets (AI Drug Discovery Leaders)

### 1. insitro
**Focus:** AI therapeutics, causal biology, drug discovery  
**Funding:** $400M+ Series C  
**HQ:** South San Francisco, CA  

| Role | Name | Email (Verified) | LinkedIn |
|------|------|------------------|----------|
| CEO & Founder | Daphne Koller | daphne@insitro.com ‚úÖ (score: 100) | linkedin.com/in/daphne-koller-4053a820 |
| Head of Drug Discovery | Philip Tagari | philip@insitro.com | linkedin.com/in/philip-tagari-793719b |

**Why PubMed API:** Integrates ML models with biological literature for target discovery
**Email Pattern:** firstname@insitro.com ‚úÖ (Hunter.io verified)  
**Website:** https://insitro.com

---

### 2. Insilico Medicine
**Focus:** AI for drug discovery end-to-end (Pharma.AI platform)  
**Funding:** $110M Series E (Jan 2025)  
**HQ:** Hong Kong / Boston / Shanghai  

| Role | Name | Contact |
|------|------|---------|
| Founder & CEO | Alex Zhavoronkov, PhD | [LinkedIn](https://linkedin.com/in/zhavoronkov) |

**Why PubMed API:** Powers PandaOmics platform for target/biomarker discovery  
**Offices:** Boston, Hong Kong, Abu Dhabi, Shanghai  
**Website:** https://insilico.com

---

### 3. Recursion Pharmaceuticals
**Focus:** AI drug discovery at scale (65+ petabytes of bio data)  
**Status:** Public (RXRX)  
**HQ:** Salt Lake City, UT  

| Role | Name | Contact |
|------|------|---------|
| CEO | Chris Gibson, PhD | [LinkedIn](https://linkedin.com/in/chrisgibsonphd) |
| CTO | Blake Borgeson | [LinkedIn](https://linkedin.com/in/blakeborgeson) |

**Why PubMed API:** Needs literature integration for BioHive-2 supercomputer workflows  
**Contact:** info@recursion.com  
**Website:** https://recursion.com

---

### 4. Isomorphic Labs (Google DeepMind)
**Focus:** AlphaFold3, AI drug discovery  
**Partners:** Eli Lilly ($3B deal), Novartis  
**HQ:** London, UK  

| Role | Name | Contact |
|------|------|---------|
| CEO | Demis Hassabis | [LinkedIn](https://linkedin.com/in/demishassabis) |

**Why PubMed API:** Literature context for protein structure predictions  
**Website:** https://isomorphiclabs.com

---

### 5. Schr√∂dinger
**Focus:** Physics-based molecular simulation for drug design  
**Status:** Public (SDGR)  
**HQ:** New York, NY  

| Role | Name | Contact |
|------|------|---------|
| President & CEO | Ramy Farid, PhD | [LinkedIn](https://linkedin.com/in/ramyfarid) |
| Chief Scientific Officer (Platform) | Robert Abel, PhD | [LinkedIn](https://linkedin.com/in/robertabelphd) |
| Chief Technology Officer | Patrick Lorton | [LinkedIn](https://linkedin.com/in/plorton) |
| Head of R&D, Therapeutics | Karen Akinsanya, PhD | [LinkedIn](https://linkedin.com/in/karen-akinsanya) |

**Why PubMed API:** Literature mining for target validation, competitive intelligence  
**Website:** https://schrodinger.com

---

## üìä Tier 2: Platform Companies (R&D Infrastructure)

### 6. Benchling
**Focus:** R&D Cloud platform for biotech  
**Employees:** 797  
**HQ:** San Francisco, CA  

| Role | Name | Contact |
|------|------|---------|
| CEO | Sajith Wickramasekara | [LinkedIn](https://linkedin.com/in/sajithw) |

**Why PubMed API:** Literature integration into R&D workflows  
**Email Pattern:** firstname@benchling.com  
**Website:** https://benchling.com

---

### 7. Tempus
**Focus:** AI precision medicine, clinical data  
**Status:** Public (TEM)  
**HQ:** Chicago, IL  

| Role | Name | Contact |
|------|------|---------|
| Founder & CEO | Eric Lefkofsky | [LinkedIn](https://linkedin.com/in/ericlefkofsky) |

**Why PubMed API:** Clinical evidence aggregation, oncology research  
**Contact:** 800.739.4137  
**Website:** https://tempus.com

---

### 8. GRAIL
**Focus:** Multi-cancer early detection (Galleri test)  
**Status:** Public (GRAL)  
**HQ:** Menlo Park, CA  

| Role | Name | Contact |
|------|------|---------|
| CEO | Bob Ragusa | [LinkedIn](https://linkedin.com/in/bobragusa) |

**Why PubMed API:** Cancer research literature, biomarker validation  
**Contact:** 833-464-7245  
**Website:** https://grail.com

---

### 9. Veracyte
**Focus:** Genomic diagnostics, precision oncology  
**Status:** Public (VCYT)  
**HQ:** South San Francisco, CA  

| Role | Name | Contact |
|------|------|---------|
| CEO | Marc Stapley | [LinkedIn](https://linkedin.com/in/marcstapley) |
| Chief Information Officer | Steven French | [LinkedIn](https://linkedin.com/in/stevenfrench) |
| Chief Scientific/Medical Officer | Phillip G. Febbo, MD | [LinkedIn](https://linkedin.com/in/phillipfebbo) |

**Why PubMed API:** Literature evidence for diagnostic validation  
**Website:** https://veracyte.com

---

### 10. PathAI
**Focus:** AI-powered pathology  
**Funding:** $165M Series C  
**HQ:** Boston, MA  

| Role | Name | Contact |
|------|------|---------|
| Co-founder & CEO | Andy Beck, MD, PhD | [LinkedIn](https://linkedin.com/in/andybeckmd) |

**Why PubMed API:** Pathology research, clinical validation literature  
**Address:** 1325 Boylston St, Suite 10000, Boston, MA 02215  
**Website:** https://pathai.com

---

## üß¨ Tier 3: AI Drug Discovery Specialists

### 11. Atomwise (now Numerion Labs)
**Focus:** AI small molecule discovery (AtomNet platform)  
**Partners:** Sanofi  
**HQ:** San Francisco, CA  

| Role | Name | Contact |
|------|------|---------|
| CEO | Abraham Heifets | [LinkedIn](https://linkedin.com/in/heifets) |

**Why PubMed API:** Target literature for 318+ target studies  
**Website:** https://atomwise.com

---

### 12. Owkin
**Focus:** Federated learning for drug discovery  
**HQ:** Paris, France / New York  

| Role | Name | Contact |
|------|------|---------|
| Chief Medical Officer | Vassili Soumelis, MD, PhD | [LinkedIn](https://linkedin.com/in/vassili-soumelis-0a0454) |
| CEO of Bioptimus | Jean-Philippe Vert, PhD | [LinkedIn](https://linkedin.com/in/djipay) |

**Why PubMed API:** Literature integration for oncology AI models  
**Website:** https://owkin.com

---

### 13. Healx
**Focus:** AI for rare disease drug discovery  
**Funding:** $73M Series B  
**HQ:** Cambridge, UK  

| Role | Name | Contact |
|------|------|---------|
| Co-founder & CEO | Tim Guilliams, PhD | [LinkedIn](https://linkedin.com/in/timguilliams) |
| Head of Operations, People & Tech | Nick Street | [LinkedIn](https://linkedin.com/in/nickstreet) |
| Director, Tech Strategy | Miguel Pignatelli | [LinkedIn](https://linkedin.com/in/miguelpignatelli) |

**Why PubMed API:** Rare disease literature mining, drug repurposing  
**Website:** https://healx.ai

---

### 14. Iktos
**Focus:** AI + robotics for small molecule discovery  
**Funding:** ‚Ç¨15.5M Series A  
**HQ:** Paris, France  

| Role | Name | Contact |
|------|------|---------|
| CEO | Yann Gaston-Math√© | [LinkedIn](https://linkedin.com/in/yanngastonmathe) |

**Why PubMed API:** Chemical synthesis validation, target research  
**Website:** https://iktos.ai

---

### 15. Cradle Bio
**Focus:** Generative AI for protein engineering  
**Funding:** $73M Series B  
**Partners:** Novo Nordisk, J&J, Grifols  
**HQ:** Amsterdam, Netherlands  

| Role | Name | Contact |
|------|------|---------|
| Co-founder & CEO | Stef van Grieken | [LinkedIn](https://linkedin.com/in/stefvangrieken) |

**Why PubMed API:** Protein research literature, therapeutic antibody development  
**Website:** https://cradle.bio

---

### 16. Absci
**Focus:** Generative AI biologics drug creation  
**Status:** Public (ABSI)  
**HQ:** Vancouver, WA  

| Role | Name | Contact |
|------|------|---------|
| Founder & CEO | Sean McClain | [LinkedIn](https://linkedin.com/in/seanmmcclain) |

**Why PubMed API:** Biologics research, AI model training  
**Website:** https://absci.com

---

### 17. Valo Health
**Focus:** End-to-end AI drug development  
**HQ:** Boston, MA  

| Role | Name | Contact |
|------|------|---------|
| CEO | Ron Hovsepian | [LinkedIn](https://linkedin.com/in/ronhovsepian) |
| Chief Information Officer | Mark Patterson | [LinkedIn](https://linkedin.com/in/markpatterson) |
| VP, Translational Data Science | Laurent Gautier | [LinkedIn](https://linkedin.com/in/laurentgautier) |

**Why PubMed API:** Clinical trial literature, target validation  
**Website:** https://valohealth.com

---

### 18. Unlearn.AI
**Focus:** Digital twins for clinical trials  
**HQ:** San Francisco, CA  

| Role | Name | Contact |
|------|------|---------|
| CEO | Charles Fisher, PhD | [LinkedIn](https://linkedin.com/in/charlesfisher) |

**Why PubMed API:** Clinical trial design, historical data analysis  
**Website:** https://unlearn.ai

---

## üìß Outreach Strategy

### Email Subject Lines
1. "PubMed API for [Company]'s AI pipeline"
2. "Faster literature access for drug discovery"
3. "Medical literature API - built for biotech"

### Value Proposition by Segment
- **AI Drug Discovery:** Integrate real-time literature into ML training pipelines
- **Platform Companies:** Embed literature search into R&D workflows
- **Diagnostics:** Clinical evidence aggregation for regulatory filings

### Common Email Pattern
Most biotech companies use: `firstname@company.com` or `firstname.lastname@company.com`

---

## üéØ Quick Reference: Top 5 Immediate Outreach

| Company | Decision Maker | Role | Why Priority |
|---------|---------------|------|--------------|
| insitro | Philip Tagari | Head of Drug Discovery | Actively building AI platform |
| Benchling | Sajith Wickramasekara | CEO | Platform for 200K+ scientists |
| Recursion | Blake Borgeson | CTO | 65PB data, needs literature integration |
| Healx | Nick Street | Head of Operations & Tech | Rare disease focus, literature-heavy |
| Schr√∂dinger | Patrick Lorton | CTO | Physics-based modeling needs validation |

---

*Generated for PubMed API sales outreach. Verify contact details before outreach.*
